Attached files

file filename
EX-99.1 - EX-99.1 - REVA Medical, Inc.a15-21258_1ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report: October 15, 2015

(Date of earliest event reported)

 

REVA MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-54192

 

33-0810505

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

5751 Copley Drive, San Diego, CA

 

92111

(Address of principal executive offices)

 

(Zip Code)

 

(858) 966-3000

(Registrant’s telephone number, including area code)

 

 

(Former Name or Former Address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 7.01   Regulation FD Disclosure

 

On October 15, 2015, REVA Medical, Inc. (“REVA” or the “Company”) announced that Dr. J. Ribamar Costa from the Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, presented clinical trial results from the Company’s FantomTM bioresorbable scaffold at the Transcatheter Therapeutics (“TCT”) conference being held in San Francisco, California, this week. The announcement and presentation materials delivered are attached hereto as Exhibit 99.1. A copy of the presentation materials will be posted under the Investor Relations section of REVA’s website at www.revamedical.com.

 

Limitation of Incorporation by Reference

 

In accordance with General Instruction B.2 of Form 8-K, this information including Exhibit 99.1 is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

 

Item 9.01   Financial Statements and Exhibits

 

(d)                   Exhibits.

 

Exhibit

 

 

Number

 

Description or Exhibits

 

 

 

99.1

 

Cover Announcement and Presentations entitled, FantomTM Differentiating Features and Clinical Trial Insights

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

REVA Medical, Inc.

 

 

Date: October 16, 2015

/s/ Katrina L. Thompson

 

Katrina L. Thompson

 

Chief Financial Officer

 

(principal financial and accounting officer)

 

3



 

Index to Exhibits

 

Exhibit

 

 

Number

 

Description or Exhibits

 

 

 

99.1

 

Cover Announcement and Presentations entitled, FantomTM Differentiating Features and Clinical Trial Insights

 

4